{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:46:05Z","timestamp":1794865565206,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) treatment can result in endocrine immune-related adverse events (irAEs), including pituitary dysfunction. Quick diagnosis of secondary adrenal insufficiency (AI) is challenging because no universal definition of ICI-induced secondary AI has been agreed. The aim of this study was to clarify the clinical features of ICI-induced secondary AI that can be used for screening in standard clinical practice. This retrospective study was performed using the medical records of patients who received ICIs at Hirosaki University Hospital between 1 September 2014 and 31 January 2021. Longitudinal clinical data of patients who developed AI were analyzed and compared with the data of thyroid irAEs. Regression analysis showed a significant correlation between ICI-induced secondary AI and absolute or relative eosinophil counts at pre-onset of AI, as well as differences or rate of increase in eosinophil counts at baseline and at pre-onset. Absolute eosinophil counts\u2009&gt;\u2009198.36\/\u00b5L or relative eosinophil counts\u2009&gt;\u20095.6% at pre-onset, and a difference of 65.25\/\u00b5L or a rate of eosinophil count increase of 1.97 between the baseline and at pre-onset showed the best sensitivity and specificity. This is the first report to demonstrate that eosinophil counts can be a predictor of ICI-induced secondary AI.<\/jats:p>","DOI":"10.1038\/s41598-022-05400-x","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T06:03:10Z","timestamp":1643090590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4759-6166","authenticated-orcid":false,"given":"Shinobu","family":"Takayasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Mizushiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Watanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Usutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Asari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Murasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Daimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"5400_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur. J. Cancer 54, 139\u2013148 (2016).","journal-title":"Eur. J. Cancer"},{"key":"5400_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa, R. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol. 4, 173\u2013182 (2018).","journal-title":"JAMA Oncol."},{"key":"5400_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje, A. et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumabassociated hypophysitis. Eur. J. Endocrinol. 181, 211\u2013219 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"5400_CR4","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","volume":"10","author":"M Stelmachowska-Bana\u015b","year":"2020","unstructured":"Stelmachowska-Bana\u015b, M. & Czajka-Oraniec, I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review. Endocr. Connect. 10, R207\u2013R228 (2020).","journal-title":"Endocr. Connect."},{"key":"5400_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein, S. R. et al. Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364\u2013389 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"5400_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1507\/endocrj.EJ16-0242","volume":"63","author":"T Yanase","year":"2016","unstructured":"Yanase, T. et al. Diagnosis and treatment of adrenal insufficiency including adrenal crisis: A Japan Endocrine Society clinical practice guideline. Endocr. J. 63, 765\u2013784 (2016).","journal-title":"Endocr. J."},{"key":"5400_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/MAJ.0b013e3181db6b7a","volume":"339","author":"B Bleicken","year":"2010","unstructured":"Bleicken, B., Hahner, S., Ventz, M. & Quinkler, M. Delayed diagnosis of adrenal insufficiency is common: A cross-sectional study in 216 patients. Am. J. Med. Sci. 339, 525\u2013531 (2010).","journal-title":"Am. J. Med. Sci."},{"key":"5400_CR8","doi-asserted-by":"publisher","first-page":"13546","DOI":"10.1038\/s41598-020-70466-4","volume":"10","author":"T Katabami","year":"2020","unstructured":"Katabami, T. et al. Development of a simple prediction model for adrenal crisis diagnosis. Sci. Rep. 10, 13546. https:\/\/doi.org\/10.1038\/s41598-020-70466-4 (2020).","journal-title":"Sci. Rep."},{"key":"5400_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa, R. et al. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer 124, 1111\u20131121 (2018).","journal-title":"Cancer"},{"key":"5400_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1507\/endocrj.EJ19-0076","volume":"66","author":"T Sekizaki","year":"2019","unstructured":"Sekizaki, T. et al. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. Endocr. J. 66, 937\u2013941 (2019).","journal-title":"Endocr. J."},{"key":"5400_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/cen.14349","volume":"94","author":"I Yamauchi","year":"2021","unstructured":"Yamauchi, I. et al. Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy. Clin. Endocrinol. (Oxf.) 94, 258\u2013268 (2021).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"5400_CR12","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir, S. A. et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl. Acad. Sci. U. S. A. 116, 22246\u201322251 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"5400_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02955-y","author":"K Kanie","year":"2021","unstructured":"Kanie, K. et al. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: A form of paraneoplastic syndrome. Cancer Immunol. Immunother. https:\/\/doi.org\/10.1007\/s00262-021-02955-y (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"5400_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/cen.14082","volume":"91","author":"H Inaba","year":"2019","unstructured":"Inaba, H. et al. Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study. Clin. Endocrinol. (Oxf.) 91, 786\u2013792 (2019).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"5400_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","volume":"130","author":"S Yano","year":"2020","unstructured":"Yano, S. et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur. J. Cancer 130, 198\u2013203 (2020).","journal-title":"Eur. J. Cancer"},{"key":"5400_CR16","first-page":"4229","volume":"37","author":"R Ariyasu","year":"2017","unstructured":"Ariyasu, R. et al. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res. 37, 4229\u20134232 (2017).","journal-title":"Anticancer Res."},{"key":"5400_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho, K. Y., Miyoshi, H., Nakamura, A., Kurita, T. & Atsumi, T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment. Endocr. J. 64, 235\u2013236 (2017).","journal-title":"Endocr. J."},{"key":"5400_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0102","author":"I Lupi","year":"2019","unstructured":"Lupi, I. et al. Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: Insights from four cases. Endocrinol. Diabetes Metab. Case Rep. https:\/\/doi.org\/10.1530\/EDM-19-0102 (2019).","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"5400_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2265.2005.02318.x","volume":"63","author":"RM Reynolds","year":"2005","unstructured":"Reynolds, R. M. & Seckl, J. R. Hyponatraemia for the clinical endocrinologist. Clin. Endocrinol. (Oxf.) 63, 366\u2013374 (2005).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"5400_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12020-017-1415-1","volume":"58","author":"D Miljic","year":"2017","unstructured":"Miljic, D. et al. Impact of etiology, age and gender on onset and severity of hyponatremia in patients with hypopituitarism: Retrospective analysis in a specialised endocrine unit. Endocrine 58, 312\u2013319 (2017).","journal-title":"Endocrine"},{"key":"5400_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1530\/EC-17-0295","volume":"6","author":"L Ferreira","year":"2017","unstructured":"Ferreira, L. et al. Adrenal Tumors Study Group of the Portuguese Society of Endocrinology. Primary adrenal insufficiency in adult population: A Portuguese multicentre study by the Adrenal Tumours Study Group. Endocr. Connect. 6, 935\u2013942 (2017).","journal-title":"Endocr. Connect."},{"key":"5400_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urolonc.2013.07.016","volume":"50","author":"Q Hu","year":"2014","unstructured":"Hu, Q. et al. The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. Urol. Oncol. 50, e1\u2013e8. https:\/\/doi.org\/10.1016\/j.urolonc.2013.07.016 (2014).","journal-title":"Urol. Oncol."},{"key":"5400_CR23","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1038\/srep10508","volume":"5","author":"L Guo","year":"2015","unstructured":"Guo, L. et al. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci. Rep. 5, 10508. https:\/\/doi.org\/10.1038\/srep10508 (2015).","journal-title":"Sci. Rep."},{"key":"5400_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s10552-015-0663-8","volume":"26","author":"HD Woo","year":"2015","unstructured":"Woo, H. D., Kim, K. & Kim, J. Association between preoperative C-reactive protein level and colorectal cancer survival: A meta-analysis. Cancer Causes Control 26, 1661\u20131670 (2015).","journal-title":"Cancer Causes Control"},{"key":"5400_CR25","doi-asserted-by":"publisher","first-page":"e8463","DOI":"10.1097\/MD.0000000000008463","volume":"96","author":"Y Fang","year":"2017","unstructured":"Fang, Y. et al. Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma: A meta-analysis and literature review. Medicine (Baltimore) 96, e8463. https:\/\/doi.org\/10.1097\/MD.0000000000008463 (2017).","journal-title":"Medicine (Baltimore)"},{"key":"5400_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jama.1948.02890460001001","volume":"137","author":"GW Thorn","year":"1948","unstructured":"Thorn, G. W., Forsham, P. H., Prunty, F. T. G. & Hills, A. G. A test for adrenal cortical insufficiency. JAMA 137, 1005\u20131009 (1948).","journal-title":"JAMA"},{"key":"5400_CR27","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(99)01346-X","volume":"353","author":"A Beishuizen","year":"1999","unstructured":"Beishuizen, A., Vermes, I., Hylkema, B. S. & Haanen, C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet 353, 1675\u20131676 (1999).","journal-title":"Lancet"},{"issue":"339","key":"5400_CR28","first-page":"e1","volume":"129","author":"TH Puar","year":"2016","unstructured":"Puar, T. H., Stikkelbroeck, N. M., Smans, L. C., Zelissen, P. M. & Hermus, A. R. Adrenal crisis: Still a deadly event in the 21st century. Am. J. Med. 129(339), e1\u2013e9 (2016).","journal-title":"Am. J. Med."},{"key":"5400_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000489341","volume":"86","author":"SA Wang","year":"2019","unstructured":"Wang, S. A. The diagnostic work-up of hypereosinophilia. Pathobiology 86, 39\u201352 (2019).","journal-title":"Pathobiology"},{"key":"5400_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","volume":"81","author":"A Bernard-Tessier","year":"2017","unstructured":"Bernard-Tessier, A. et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur. J. Cancer 81, 135\u2013137 (2017).","journal-title":"Eur. J. Cancer"},{"key":"5400_CR31","doi-asserted-by":"publisher","first-page":"1722022","DOI":"10.1080\/2162402X.2020.1722022","volume":"9","author":"Q Scanvion","year":"2020","unstructured":"Scanvion, Q. et al. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. Oncoimmunology 9, 1722022. https:\/\/doi.org\/10.1080\/2162402X.2020.1722022 (2020).","journal-title":"Oncoimmunology"},{"key":"5400_CR32","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2020-0070","author":"T Krishnan","year":"2020","unstructured":"Krishnan, T., Tomita, Y. & Roberts-Thomson, R. A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy. Future Sci. OA https:\/\/doi.org\/10.2144\/fsoa-2020-0070 (2020).","journal-title":"Future Sci. OA"},{"key":"5400_CR33","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.23217","volume":"8","author":"A Diehl","year":"2017","unstructured":"Diehl, A., Yarchoan, M., Hopkins, A., Jaffee, E. & Grossman, S. A. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8, 114268\u2013114280 (2017).","journal-title":"Oncotarget"},{"key":"5400_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jjco\/hyy201","volume":"49","author":"Y Nakamura","year":"2019","unstructured":"Nakamura, Y. et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn. J. Clin. Oncol. 49, 431\u2013437 (2019).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"5400_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","volume":"68","author":"SCS Simon","year":"2019","unstructured":"Simon, S. C. S., Utikal, J. & Umansky, V. Opposing roles of eosinophils in cancer. Cancer Immunol. Immunother. 68, 823\u2013833 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"5400_CR36","doi-asserted-by":"publisher","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","volume":"8","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi, T. et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: A prospective study. J. Immunother. Cancer 8, e000779. https:\/\/doi.org\/10.1136\/jitc-2020-000779 (2020).","journal-title":"J. Immunother. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05400-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:25:48Z","timestamp":1669307148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5400"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05400-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"3 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ST receives personal fees from Ono Pharmaceutical Company. KK receives personal fees from Ono Pharmaceutical Company. MD receives personal fees from Ono Pharmaceutical Company. SM, YW, SY, YN, MU, YA, and SM do not have any competing interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1294"}}